CIN No.: L74900MH2013PLC244717

Aakaar Medical Technologies Limited
(formerly: Aakaar Medical Technologies Pvt.Ltd.)
A-801, Heritage Plaza, Teli Gali Cross Road
Andheri (East), Mumbai – 400 069 INDIA
Mob: + 91 9136923652
E-mail: info@aakaarmedical.in
www.aakaarmedical.in
GST No: 27AALCA7587Q1ZK

24th July, 2026

To,
The Manager,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, C-1,
Block- G, Bandra – Kurla Complex,
Bandra (East), Mumbai – 400051.
Symbol: AAKAAR

Dear Sir,

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Operational Business Update for the Quarter ended June 30, 2026.

Dear Sir,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable provisions, we are pleased to submit the enclosed Operational business update of Aakaar Medical Technologies Limited for the quarter ended June 30, 2026, as Annexure–A.

The enclosed update provides an overview of the Company's key operational developments during the quarter, including business growth indicators.

The operational information contained in the enclosed annexure is based on internal management information systems and is being shared as part of the Company's investor communication initiatives. This disclosure does not constitute the financial results of the Company. The above information is subject to limited review / audit by the Statutory Auditors of the Company. The company will continue to keep the stock exchange informed of all material developments in compliance with applicable regulations.

Kindly take the above information on record.

Thanking you.

Yours faithfully,
For Aakaar Medical Technologies Ltd.

VISHWANATHAN ANOOPKUMAR PILLAI
Digitally signed by VISHWANATHAN ANOOPKUMAR PILLAI
Date: 2026.07.24 22:21:58 +05'30'

Anoopkumar Pillai
Company Secretary & Compliance Officer

Encl: Annexure-A.

Aākaar
enhancing life through technology
CIN No.: L74900MH2013PLC244717

Aakaar Medical Technologies Limited
(formerly: Aakaar Medical Technologies Pvt.Ltd.)
A-801, Heritage Plaza, Teli Gali Cross Road
Andheri (East), Mumbai – 400 069 INDIA
Mob: + 91 9136923652
E-mail: info@aakaarmedical.in
www.aakaarmedical.in
GST No: 27AALCA7587Q1ZK

AAKAAR MEDICAL TECHNOLOGIES LTD

Operational Business Update

Q1 FY2026-27

MESSAGE FROM THE MANAGING DIRECTOR & CEO

FY26 marked an important phase in Aakaar's transformation. The strategic initiatives undertaken during the second half of the year are beginning to translate into stronger operational execution, improved commercial discipline and continued expansion of our medical aesthetics ecosystem.

During Q1 FY2026-27, we remained focused on strengthening our distribution network, expanding scientific engagement, accelerating innovation, improving digital execution and building recurring revenue platforms. The operational momentum established during H2 FY26 has continued into the current financial year and reinforces our confidence in the Company's long-term strategy.

Our objective remains clear: build a high quality, science driven organisation capable of delivering sustainable growth, profitability and long-term value for doctors, customers, employees and shareholders.

Key Highlights

6,700+ DOCTORS & CLINICS	**35** DISTRIBUTORS	**24** HQ DISTRIBUTOR CITIES	**28** XELIX CLINICS AS ON DATE	**21** XELIX CLINICS IN Q1
45 WORKSHOPS	**308** DOCTORS TRAINED	**9** CONFERENCES	**3,100+** DOCTORS REACHED	**150** FIELD FORCE

Accelerating Xelix Clinic Expansion

- 28 clinics enrolled across 14 cities.
- 21 clinics onboarded during Q1.
- 19 clinics fully branded.
- Expansion pipeline continues across key markets.
- Targeting to reach 50 clinics in H1 and 100 by H2 end.

Aakaar Medical Technologies Limited
(formerly: Aakaar Medical Technologies Pvt.Ltd.)
A-801, Heritage Plaza, Teli Gali Cross Road
Andheri (East), Mumbai – 400 069 INDIA
Mob: + 91 9136923652
E-mail: info@aakaarmedical.in
www.aakaarmedical.in
GST No: 27AALCA7587Q1ZK

FY27 Outlook and Guidance – Clear Roadmap - Sustainable Growth.

- FY27 revenue growth guidance of approximately 30% and subject to said achievement EBITDA growth guidance of approximately 25%.
- Business momentum remains aligned with the Company's long-term growth trajectory, supported by a strengthened distribution platform, expanding doctor network, deeper scientific engagement and continued innovation.
- Debtor days targeted to improve to 120–130 days by FY27-end, following the completion of the distribution transformation.

Strengthening Distribution Network

- Novacare Healthcare Solutions appointed as national CFA partner.
- 35 distributors appointed across 24 cities.
- Migration to the new CFA and distributor model targeted for completion by mid August 2026.
- Focus on improving receivables, working capital efficiency and debtor days.

Expanding Clinical Reach & Product Adoption

- Continued expansion of LETYBO, SAYPHA and XOMAGE reaching clinics looking for world class solutions.
- DRS1512 clinical data shows great promise in hair fall management in an ongoing clinical trial by dermatologists.
- 45 workshops conducted, 308 doctors trained and participation in 9 scientific conferences reaching over 3,100+ dermatologists.

Driving Sales Force Effectiveness

- Sales CRM deployed across 150 field professionals.
- Targeting average 5 doctor calls per representative per day.
- More than 10,000+ doctor interactions are monitored each month.

Disclaimer

This Operational Business Update is intended to provide an overview of the Company's operational progress during the quarter ended 30 June 2026 and should not be construed as a financial results announcement. Financial information, where applicable, remains subject to statutory audit, limited review and approval by the Board of Directors, as required under applicable laws and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The performance indicators included in this Investor Update are derived from the Company's unaudited management accounts prepared in accordance with the Company's accounting policies. The

Aakaar Medical Technologies Limited
(formerly: Aakaar Medical Technologies Pvt.Ltd.)
A-801, Heritage Plaza, Teli Gali Cross Road
Andheri (East), Mumbai – 400 069 INDIA
Mob: + 91 9136923652
E-mail: info@aakaarmedical.in
www.aakaarmedical.in
GST No: 27AALCA7587Q1ZK

Company is not required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to submit quarterly financial results for the quarter ended 30 June 2026. Accordingly, these indicators do not constitute financial results under Regulation 33. Further certain matters discussed in this Investor update may contain statements regarding the company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied . The Company assumes no obligation to update any forward-looking information contained in this Investor update. The company will continue to keep the National Stock Exchange informed of all material developments in compliance with applicable regulations.